SuperworthResMed RMD
- Market cap
- $36.5B
- PE
- 24.2×
- 10y median 37.3×
- Forward PE
- 20.8×
- 10y median 29.1×
- Price to sales
- 6.5×
- EV/EBIT
- 18.7×
- Revenue, 12 months
- $5.7B
- +10% on a year ago
- Net margin
- 26.9%
- Free cash flow yield
- 4.5%
ResMed trades at 24.2× trailing earnings, cheaper than 91% of the last ten years. Revenue was $5.7B over the last twelve months, up 10% on a year earlier with a 27% net margin.
Charts
Financials
| Income statement | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $1.1B+16% | $1.2B+13% | $1.2B+7% | $1.2B+9% | $1.2B+11% | $1.3B+10% | $1.3B+8% | $1.3B+10% | $1.3B+9% | $1.4B+11% | $1.4B+11% | $1.5B+9% | |
| Cost of revenue | $502.3M+23% | $515.9M+14% | $504.2M+1% | $507.7M+1% | $507.3M+1% | $530.8M+3% | $525.3M+4% | $527.9M+4% | $514.8M+2% | $544.1M+3% | $540.4M+3% | $602.4M+14% |
| Gross profit | $600.1M+11% | $646.9M+12% | $692.8M+12% | $715.5M+16% | $717.2M+20% | $751.3M+16% | $766.4M+11% | $820.1M+15% | $820.8M+14% | $878.7M+17% | $891M+16% | $861.2M+5% |
| R&D | $75.7M+20% | $73.9M+6% | $77.1M+1% | $80.9M+4% | $79.5M+5% | $81.4M+10% | $83.9M+9% | $86.4M+7% | $87.3M+10% | $91M+12% | $94.3M+12% | $105.7M+22% |
| SG&A | $222.9M+15% | $222.2M+5% | $229.9M+1% | $242.2M+1% | $239M+7% | $241.6M+9% | $245.3M+7% | $267.2M+10% | $259.2M+9% | $278.4M+15% | $285.7M+17% | $296.3M+11% |
| $289M+5% | $275.1M−2% | $374.6M+25% | $381.2M+39% | $387.3M+34% | $417.2M+52% | $426.3M+14% | $454.5M+19% | $446.5M+15% | $491.7M+18% | $499.8M+17% | $448.7M−1% | |
| Interest expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Pre-tax income | $272.2M+4% | $259.5M−5% | $375.4M+30% | $357.7M+29% | $383.5M+41% | $418.3M+61% | $417.7M+11% | $458.1M+28% | $446.8M+17% | $496.1M+19% | $502.3M+20% | $474.2M+4% |
| $52.8M+3% | $50.7M+4% | $74.9M+32% | $65.5M+39% | $72.1M+37% | $73.7M+46% | $52.7M−30% | $78.3M+20% | $98.3M+36% | $103.6M+41% | $103.6M+97% | $90.7M+16% | |
| Net income | $219.4M+4% | $208.8M−7% | $300.5M+29% | $292.2M+27% | $311.4M+42% | $344.6M+65% | $365M+22% | $379.7M+30% | $348.5M+12% | $392.6M+14% | $398.7M+9% | $383.4M+1% |
| $1.49+4% | $1.42−7% | $2.04+29% | $1.98+27% | $2.11+42% | $2.34+65% | $2.48+22% | $2.58+30% | $2.37+12% | $2.68+15% | $2.74+11% | $2.64+2% | |
| 147.5M+0% | 147.5M+0% | 147.4M+0% | 147.6M+0% | 147.6M+0% | 147.5M+0% | 147.2M−0% | 147.1M−0% | 146.9M−1% | 146.4M−1% | 145.7M−1% | 145.1M−1% |
EPS, diluted: 17 periods, Q4 FY10 to Q4 FY26: quarter's net income to common over its shares, to the cent.
Diluted shares: 17 periods, Q4 FY10 to Q4 FY26: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Estimates
Next earnings report: .
| Quarter | Revenue | Range | EPS | Range | Analysts |
|---|---|---|---|---|---|
| Q1 FY27 | $1.4B | $1.4B to $1.4B | $2.69 | $2.65 to $2.73 | 9 |
| Q2 FY27 | $1.5B | $1.4B to $1.5B | $3.03 | $3.00 to $3.10 | 9 |
| Q3 FY27 | $1.5B | $1.5B to $1.5B | $3.15 | $3.13 to $3.19 | 6 |
| Q4 FY27 | $1.5B | $1.5B to $1.5B | $3.28 | $3.26 to $3.32 | 3 |
| Q1 FY28 | $1.5B | $1.5B to $1.5B | $2.99 | $2.97 to $3.03 | 3 |
| Q2 FY28 | $1.5B | $1.5B to $1.6B | $3.33 | $3.31 to $3.38 | 6 |
| Q3 FY28 | $1.6B | $1.5B to $1.6B | $3.40 | $3.38 to $3.45 | 8 |
| Q4 FY28 | $1.6B | $1.6B to $1.6B | $3.51 | $3.49 to $3.56 | 4 |
Peers
Companies in Medical - Instruments & Supplies nearest ResMed's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| RMDResMed | $36.5B | 24.2× | 37.3× | 20.8× | 6.5× | +10% | 26.9% |
| MDLNMedline | $44.8B | n/m | n/a | 23.2× | n/m | n/m | n/m |
| WSTWest Pharmaceutical Services | $27.6B | 50.2× | 45.8× | 42.2× | 8.3× | +12% | 17.0% |
| BDXBecton, Dickinson and | $54.2B | 60.1× | 37.5× | 15.1× | 2.6× | +5% | 4.5% |
| SOLVSolventum | $14.5B | 10.4× | 10.7× | n/m | 1.7× | −1% | 17.3% |
| PENPenumbra | $12.8B | 79.7× | 197× | n/m | 8.5× | +18% | 10.7% |
| COOCooper Companies | $11.6B | 20.9× | 40.2× | n/m | 2.7× | +5% | 13.5% |
| ALGNAlign Technology | $11B | 26.9× | 43.3× | n/m | 2.7× | +4% | 10.0% |
| GMEDGlobus Medical | $10.9B | 20.8× | 37.4× | n/m | 3.5× | +20% | 17.0% |
| PODDInsulet | $10.3B | 27.9× | 63.0× | n/m | 3.4× | +29% | 12.3% |
| ISRGIntuitive Surgical | $159.8B | 54.7× | 69.3× | 37.5× | 13.8× | +20% | 25.5% |
| Peer median | $13.7B | 27.9× | 43.3× | 30.4× | 3.4× | +12% | 13.5% |
Investors who own it
Investors we follow who held ResMed at the end of Jun 30, 2026, from their 13F filings.
- François RochonGiverny Capital2.5% of portfolioadded
More on ResMed
Each number over time
- PE ratio
- Forward PE
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Dividend yield
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #2of 80Medical instruments and supplies stocks with the highest profit margins
- #5of 23Medical instruments and supplies stocks cheapest against their own PE history
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .